Actuate Therapeutics, Inc. (ACTU)
NASDAQ:ACTU
ACTU Stock Chart & Stats
$1.72
-$0.11(-1.36%)
At close: 4:00 PM EST
$1.72
-$0.11(-1.36%)
Day’s Range― - ―
52-Week Range$1.69 - $11.99
Previous CloseN/A
Volume10.16K
Average Volume (3M)94.47K
Market Cap
$40.78M
Enterprise Value$30.40M
Total Cash (Recent Filing)$13.16M
Total Debt (Recent Filing)$404.99K
Price to Earnings (P/E)―
Beta1.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding23,709,944
10 Day Avg. Volume91,719
30 Day Avg. Volume94,472
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)16.24
Price to Sales (P/S)0.00
P/FCF Ratio-6.70
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.36
Forecast
1Y Price Target
$20.00Price Target Upside1062.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.88
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyRandomized Phase 2 results showing an overall survival improvement for the drug combined with standard chemotherapy provide a persuasive efficacy signal that could justify confirmation in a pivotal study and enhance future market potential.
Pediatric DevelopmentObserved complete responses in pediatric patients with Ewing sarcoma and neuroblastoma support planned pediatric Phase 2 trials and could unlock regulatory incentives and new indications if confirmed.
Regulatory StrategyPlanned regulatory meetings to finalize Phase 3 design for metastatic pancreatic cancer could support initiation of a pivotal trial and clarify the pathway toward potential approval and commercialization.
Bears Say
Development Timeline And CostsSafety signals combined with lack of expedited pathway may necessitate additional studies or protocol changes, which could delay pivotal trials and increase development expenses.
Regulatory Designation RiskRegulatory authorities declined expedited designation due to expectations of a clear and substantial benefit over existing therapies, increasing uncertainty around accelerated approval options.
Safety ProfileA notably higher rate of severe neutropenia in the drug arm raises tolerability and safety concerns that could affect trial acceptability and clinical adoption if not mitigated.
Actuate Therapeutics, Inc. News
ACTU FAQ
What was Actuate Therapeutics, Inc.’s price range in the past 12 months?
Actuate Therapeutics, Inc. lowest stock price was $1.69 and its highest was $11.99 in the past 12 months.
What is Actuate Therapeutics, Inc.’s market cap?
Actuate Therapeutics, Inc.’s market cap is $40.78M.
When is Actuate Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Actuate Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Actuate Therapeutics, Inc. overvalued?
According to Wall Street analysts Actuate Therapeutics, Inc.’s price is currently Undervalued.
Does Actuate Therapeutics, Inc. pay dividends?
Actuate Therapeutics, Inc. does not currently pay dividends.
What is Actuate Therapeutics, Inc.’s EPS estimate?
Actuate Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actuate Therapeutics, Inc. have?
Actuate Therapeutics, Inc. has 23,709,944 shares outstanding.
What happened to Actuate Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Actuate Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACTU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Actuate Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (1062.79% Upside)
$20.00 (1062.79% Upside)
Blogger Sentiment
Bullish
ACTU Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 8.2%
Last 30 Days ▲ 8.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.80%
12-Months-Change
Fundamentals
Return on Equity
-799.65%
Trailing 12-Months
Asset Growth
50.62%
Trailing 12-Months
Company Description
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
ACTU Stock 12 Month Forecast
Average Price Target
$20.00
▲(1062.79% Upside)
Technical Analysis
Agenus
―
Black Diamond Therapeutics
―
Nkarta
―
C4 Therapeutics
―
Kyverna Therapeutics, Inc.
―